CLIN CANCER RES:镭223联合VEGF靶向疗法治疗晚期肾细胞癌

2018-09-05 MedSci MedSci原创

CLIN CANCER RES近期发表了一篇文章,研究镭223联合VEGF靶向疗法治疗伴有骨转移的晚期肾细胞癌患者的抗肿瘤活性。

CLIN CANCER RES近期发表了一篇文章,研究镭223联合VEGF靶向疗法治疗伴有骨转移的晚期肾细胞癌患者的抗肿瘤活性。

15例未接受过治疗的患者接受Pazopanib 800mg口服每天一次,15例进行过治疗的患者接受sorafenib 400mg口服每天两次。两组均同时每四周注射镭223至6个周期。主要的研究终点为骨循环标志物(Ⅰ型前胶原,氨基末端肽,C端肽,骨钙素和骨特异性碱性磷酸酶)下降情况。次要的研究终点包括安全性,有症状骨骼事件发生率和出现第一次有症状骨骼事件的时间,客观缓解率,止痛剂使用情况以及生活质量。对肿瘤遗传学改变也进行了探索性研究。纳入的30例患者中,33%存在肝转移,83%在入组前存在有症状的骨骼事件。未发现剂量限制毒性。在第8周和第16周,所有的骨循环标志物均显着下降。40%的患者出现治疗相关≥3级不良反应。在Pazopanib队列和sorafenib队列中客观缓解率分别为15%和18%,骨缓解率分别为50%和30%。中位无有症状骨骼事件的时间为5.8个月。在研究期间止痛剂使用平稳。

文章最后认为,镭223联合VEGF靶向疗法具有生物学活性及安全性。需要RCT试验验证镭223治疗伴有骨转移的晚期肾细胞癌患者的作用。

原始出处:
Rana R Mckay,Dominick Bosse,et al.Radium-223 Dichloride in Combination with Vascular Endothelial Growth Factor-Targeting Therapy in Advanced Renal Cell Carcinoma with Bone Metastases.CLIN CANCER RES.September 2018 doi:10.1158/1078-0432.CCR-17-3577

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1978739, encodeId=a3b919e873910, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Fri Aug 02 05:33:00 CST 2019, time=2019-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368505, encodeId=207f136850558, content=<a href='/topic/show?id=25aa1833e88' target=_blank style='color:#2F92EE;'>#VEGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18337, encryptionId=25aa1833e88, topicName=VEGF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80ca273, createdName=fanweitanzhen, createdTime=Fri Sep 07 10:33:00 CST 2018, time=2018-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378542, encodeId=ddec13e854254, content=<a href='/topic/show?id=2cf09992871' target=_blank style='color:#2F92EE;'>#靶向疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99928, encryptionId=2cf09992871, topicName=靶向疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b676418, createdName=yanghan, createdTime=Fri Sep 07 10:33:00 CST 2018, time=2018-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441744, encodeId=7c0a1441e44e3, content=<a href='/topic/show?id=09a6598e57a' target=_blank style='color:#2F92EE;'>#晚期肾细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59875, encryptionId=09a6598e57a, topicName=晚期肾细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=87304889998, createdName=12498c24m70暂无昵称, createdTime=Fri Sep 07 10:33:00 CST 2018, time=2018-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568643, encodeId=20e91568643a6, content=<a href='/topic/show?id=2708968506f' target=_blank style='color:#2F92EE;'>#镭223#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96850, encryptionId=2708968506f, topicName=镭223)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=121015405421, createdName=hywen7331, createdTime=Fri Sep 07 10:33:00 CST 2018, time=2018-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=343230, encodeId=8ec5343230ec, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Thu Sep 06 08:01:12 CST 2018, time=2018-09-06, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1978739, encodeId=a3b919e873910, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Fri Aug 02 05:33:00 CST 2019, time=2019-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368505, encodeId=207f136850558, content=<a href='/topic/show?id=25aa1833e88' target=_blank style='color:#2F92EE;'>#VEGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18337, encryptionId=25aa1833e88, topicName=VEGF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80ca273, createdName=fanweitanzhen, createdTime=Fri Sep 07 10:33:00 CST 2018, time=2018-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378542, encodeId=ddec13e854254, content=<a href='/topic/show?id=2cf09992871' target=_blank style='color:#2F92EE;'>#靶向疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99928, encryptionId=2cf09992871, topicName=靶向疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b676418, createdName=yanghan, createdTime=Fri Sep 07 10:33:00 CST 2018, time=2018-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441744, encodeId=7c0a1441e44e3, content=<a href='/topic/show?id=09a6598e57a' target=_blank style='color:#2F92EE;'>#晚期肾细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59875, encryptionId=09a6598e57a, topicName=晚期肾细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=87304889998, createdName=12498c24m70暂无昵称, createdTime=Fri Sep 07 10:33:00 CST 2018, time=2018-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568643, encodeId=20e91568643a6, content=<a href='/topic/show?id=2708968506f' target=_blank style='color:#2F92EE;'>#镭223#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96850, encryptionId=2708968506f, topicName=镭223)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=121015405421, createdName=hywen7331, createdTime=Fri Sep 07 10:33:00 CST 2018, time=2018-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=343230, encodeId=8ec5343230ec, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Thu Sep 06 08:01:12 CST 2018, time=2018-09-06, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1978739, encodeId=a3b919e873910, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Fri Aug 02 05:33:00 CST 2019, time=2019-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368505, encodeId=207f136850558, content=<a href='/topic/show?id=25aa1833e88' target=_blank style='color:#2F92EE;'>#VEGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18337, encryptionId=25aa1833e88, topicName=VEGF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80ca273, createdName=fanweitanzhen, createdTime=Fri Sep 07 10:33:00 CST 2018, time=2018-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378542, encodeId=ddec13e854254, content=<a href='/topic/show?id=2cf09992871' target=_blank style='color:#2F92EE;'>#靶向疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99928, encryptionId=2cf09992871, topicName=靶向疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b676418, createdName=yanghan, createdTime=Fri Sep 07 10:33:00 CST 2018, time=2018-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441744, encodeId=7c0a1441e44e3, content=<a href='/topic/show?id=09a6598e57a' target=_blank style='color:#2F92EE;'>#晚期肾细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59875, encryptionId=09a6598e57a, topicName=晚期肾细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=87304889998, createdName=12498c24m70暂无昵称, createdTime=Fri Sep 07 10:33:00 CST 2018, time=2018-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568643, encodeId=20e91568643a6, content=<a href='/topic/show?id=2708968506f' target=_blank style='color:#2F92EE;'>#镭223#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96850, encryptionId=2708968506f, topicName=镭223)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=121015405421, createdName=hywen7331, createdTime=Fri Sep 07 10:33:00 CST 2018, time=2018-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=343230, encodeId=8ec5343230ec, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Thu Sep 06 08:01:12 CST 2018, time=2018-09-06, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1978739, encodeId=a3b919e873910, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Fri Aug 02 05:33:00 CST 2019, time=2019-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368505, encodeId=207f136850558, content=<a href='/topic/show?id=25aa1833e88' target=_blank style='color:#2F92EE;'>#VEGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18337, encryptionId=25aa1833e88, topicName=VEGF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80ca273, createdName=fanweitanzhen, createdTime=Fri Sep 07 10:33:00 CST 2018, time=2018-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378542, encodeId=ddec13e854254, content=<a href='/topic/show?id=2cf09992871' target=_blank style='color:#2F92EE;'>#靶向疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99928, encryptionId=2cf09992871, topicName=靶向疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b676418, createdName=yanghan, createdTime=Fri Sep 07 10:33:00 CST 2018, time=2018-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441744, encodeId=7c0a1441e44e3, content=<a href='/topic/show?id=09a6598e57a' target=_blank style='color:#2F92EE;'>#晚期肾细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59875, encryptionId=09a6598e57a, topicName=晚期肾细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=87304889998, createdName=12498c24m70暂无昵称, createdTime=Fri Sep 07 10:33:00 CST 2018, time=2018-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568643, encodeId=20e91568643a6, content=<a href='/topic/show?id=2708968506f' target=_blank style='color:#2F92EE;'>#镭223#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96850, encryptionId=2708968506f, topicName=镭223)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=121015405421, createdName=hywen7331, createdTime=Fri Sep 07 10:33:00 CST 2018, time=2018-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=343230, encodeId=8ec5343230ec, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Thu Sep 06 08:01:12 CST 2018, time=2018-09-06, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1978739, encodeId=a3b919e873910, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Fri Aug 02 05:33:00 CST 2019, time=2019-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368505, encodeId=207f136850558, content=<a href='/topic/show?id=25aa1833e88' target=_blank style='color:#2F92EE;'>#VEGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18337, encryptionId=25aa1833e88, topicName=VEGF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80ca273, createdName=fanweitanzhen, createdTime=Fri Sep 07 10:33:00 CST 2018, time=2018-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378542, encodeId=ddec13e854254, content=<a href='/topic/show?id=2cf09992871' target=_blank style='color:#2F92EE;'>#靶向疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99928, encryptionId=2cf09992871, topicName=靶向疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b676418, createdName=yanghan, createdTime=Fri Sep 07 10:33:00 CST 2018, time=2018-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441744, encodeId=7c0a1441e44e3, content=<a href='/topic/show?id=09a6598e57a' target=_blank style='color:#2F92EE;'>#晚期肾细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59875, encryptionId=09a6598e57a, topicName=晚期肾细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=87304889998, createdName=12498c24m70暂无昵称, createdTime=Fri Sep 07 10:33:00 CST 2018, time=2018-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568643, encodeId=20e91568643a6, content=<a href='/topic/show?id=2708968506f' target=_blank style='color:#2F92EE;'>#镭223#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96850, encryptionId=2708968506f, topicName=镭223)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=121015405421, createdName=hywen7331, createdTime=Fri Sep 07 10:33:00 CST 2018, time=2018-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=343230, encodeId=8ec5343230ec, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Thu Sep 06 08:01:12 CST 2018, time=2018-09-06, status=1, ipAttribution=)]
    2018-09-07 hywen7331
  6. [GetPortalCommentsPageByObjectIdResponse(id=1978739, encodeId=a3b919e873910, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Fri Aug 02 05:33:00 CST 2019, time=2019-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368505, encodeId=207f136850558, content=<a href='/topic/show?id=25aa1833e88' target=_blank style='color:#2F92EE;'>#VEGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18337, encryptionId=25aa1833e88, topicName=VEGF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80ca273, createdName=fanweitanzhen, createdTime=Fri Sep 07 10:33:00 CST 2018, time=2018-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378542, encodeId=ddec13e854254, content=<a href='/topic/show?id=2cf09992871' target=_blank style='color:#2F92EE;'>#靶向疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99928, encryptionId=2cf09992871, topicName=靶向疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b676418, createdName=yanghan, createdTime=Fri Sep 07 10:33:00 CST 2018, time=2018-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441744, encodeId=7c0a1441e44e3, content=<a href='/topic/show?id=09a6598e57a' target=_blank style='color:#2F92EE;'>#晚期肾细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59875, encryptionId=09a6598e57a, topicName=晚期肾细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=87304889998, createdName=12498c24m70暂无昵称, createdTime=Fri Sep 07 10:33:00 CST 2018, time=2018-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568643, encodeId=20e91568643a6, content=<a href='/topic/show?id=2708968506f' target=_blank style='color:#2F92EE;'>#镭223#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96850, encryptionId=2708968506f, topicName=镭223)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=121015405421, createdName=hywen7331, createdTime=Fri Sep 07 10:33:00 CST 2018, time=2018-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=343230, encodeId=8ec5343230ec, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Thu Sep 06 08:01:12 CST 2018, time=2018-09-06, status=1, ipAttribution=)]
    2018-09-06 kafei

    学习了谢谢

    0

相关资讯

Nat Med:单独atezolizumab或者atezolizumab结合贝伐单抗与舒尼替尼在肾细胞癌中治疗的临床活性和相关分子响应比较研究

最近,有研究人员阐述了 IMmotion150的研究结果,该研究是一个随机的阶段2研究,具体包括了305名从未治疗过的转移性肾细胞癌患者,并且利用单独的atezolizumab(anti-PD-L1)或者结合贝伐单抗(anti-VEGF)与舒尼替尼治疗结果的比较。主要结果为在意向治疗中的无进展自由生存(PFS)和PD-L1+群体。研究发现,atezolizumab+贝伐单抗或者atezolizum

Oncogene:谷胱甘肽氧化还原系统对预防透明细胞肾细胞癌中受损脂质代谢引起的铁死亡是必需的

代谢重编程是透明细胞肾细胞癌(ccRCC)的一个显著的特性。最近,有研究人员在一系列的ccRCC细胞系中利用营养缺失、功能性RNAi筛选和抑制剂处理调查了代谢依赖性。研究人员发现,ccRCC细胞对谷氨酰胺或者胱氨酸的缺失高度敏感。这两种氨基酸对谷胱甘肽(GSH)的合成是需要的。更多的是,GSH生物合成通路相关酶的沉默或者谷胱甘肽过氧物酶的沉默能够选择性的减少ccRCC细胞的生存,但是并不影响良性肾

Sci Rep:肾细胞癌中细胞自噬缺陷和相关的遗传变异研究

细胞自噬与肿瘤之间的关系已经研究的很详细,但是肿瘤细胞形态的变化相关的细胞自噬缺陷却报道很少,尤其是在肾细胞癌中(RCC)。最近,有研究人员搜集了10个肾肿瘤样本,这些样本均具有特有的嗜酸性胞浆内包涵体(ECIs),并且研究人员发现这些ECIs主要是由sequestosome 1/P62组成,并且与BRCA1基因(NBR1)、PEX14和CATALASE1(CAT1)近邻。更进一步的是,透射电镜分

NEJM:转移性肾细胞癌患者单纯或肾切除术后舒尼替尼疗效研究

研究发现,对于转移性肾细胞癌患者,舒尼替尼治疗与舒尼替尼联合手术治疗对患者生存期的影响差异不显著

Oncogene:Lim1致瘤基因是转移性人类肾细胞癌的新的治疗靶标

尽管在抗血管生成靶向治疗和免疫检查点抑制剂的发现中具有进步和发展,但是转移性透明肾细胞癌(CCC)仍旧是不可治愈的。研究人员之前报道了sonic hedgehog-Gli信号通路在CCC中是致瘤性的,这也让研究人员在CCC中鉴定了发育Lim1转录因子可作为Gli靶标和CCC中一个新的可调控细胞增殖和凋亡的致瘤基因,并且能够促进肿瘤生长。之前研究的初级体外试验结果同样表明了Lim1可能在转移性传播中

Brit J Cancer:类血管生成素蛋白3能够阻断FAK的细胞核输入并有助于索拉非尼响应

索拉非尼不良的药物反应是一个重要的挑战。不良药物反应减少了肾细胞癌(RCC)患者的临床益处。因此,阐释恢复索拉非尼治疗响应的潜在机制具有中重要的意义。最近,有研究人员利用蛋白免疫印迹和免疫组化技术在2个RCC患者群体中测量了类血管生成素蛋白3(ANGPTL3)含量水平。在RCC细胞中,研究人员利用功能丧失和功能获得试验用来调查ANGPTL3在索拉非尼治疗中的生物学作用,还利用人类蛋白组芯片和免疫沉